Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (5): 25-30.doi: 10.6040/j.issn.1671-7554.0.2022.0803

• 临床医学 • Previous Articles    

A retrospective analysis of 31 patients with acquired coagulation factor deficiency

SHANG Yangli, ZHONG Guangcai, LI Shijie, SUN Mingshan, CHEN Chunyan   

  1. Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2023-05-15

PDF (PC)

68

Abstract: Objective To explore the etiology, clinical manifestations, treatment and outcomes of acquired coagulation factor deficiency. Methods Clinical data of 31 patients with acquired coagulation factor deficiency during Jul. 2011 and Oct. 2021 were retrospectively analyzed. Patients with acquired hemophilia A(AHA)were grouped according to FⅧ inhibitor levels and intergroup correlation analysis was conducted. Results Of the 31 cases, 29 were AHA and 2 were acquired coagulation factor V deficiency(AFVD). The most common clinical symptoms of AHA were subcutaneous bleeding(62.07%)and muscle and soft tissue hematoma(34.48%). The AFVD patients had symptoms of hematuria and skin hemorrhagic spots. Patients with higher FⅧ inhibitor titer had longer activated partial thromboplastin time and lower level of FⅧ: C(P<0.05), but there was no correlation between the level of FⅧ inhibitor titer and severity of bleeding. Conclusion Screening the etiology of patients, combined with the comprehensive evaluation of the etiology, age, underlying diseases, levels of coagulation factors and other indicators to formulate an individualized treatment plan, has an important guiding significance for the clinical management of acquired coagulation factor deficiency.

Key words: Acquired hemophilia A, Coagulation factor deficiency, Inhibitor, Immunosuppressive agents

CLC Number: 

  • R552
[1] 中华医学会血液学分会血栓与止血学组,中国血友病协作组. 凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版)[J]. 中华血液学杂志, 2018, 39(10): 793-799. Thrombosis and Hemostasis Group of Hematology Branch of Chinese Medical Association,Hemophilia Collaborative Group.Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors(version 2018)[J]. Chinese Journal of Hematology, 2018, 39(10): 793-799.
[2] 中国研究型医院学会血栓与止血专委会. 活化部分凝血活酶时间延长混合血浆纠正试验操作流程及结果解读中国专家共识[J]. 中华检验医学杂志, 2021, 44(8): 690-697. Special Committee on Thrombosis and Hemostasis of China Research Hospital Association. Chinese expert consensus on operation procedure and result interpretation of APTT mixing test [J]. Chinese Journal of Laboratory Medicine, 2021, 44(8): 690-697.
[3] 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 获得性血友病A诊断与治疗中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(10): 793-799. Thrombosis and Hemostasis Group of Hematology Branch of Chinese Medical Association, Hemophilia Collaborative Group. Chinese guidelines on the diagnosis and treatment of acquired hemophilia A(2021)[J]. Chinese Journal of Hematology, 2021, 42(10): 793-799.
[4] Kadohira Y, Yamada S, Hayashi T, et al. A discrepancy between prothrombin time and Normotest(Hepaplastintest)results is useful for diagnosis of acquired factor V inhibitors [J]. Int J Hematol, 2018, 108(2): 145-150.
[5] 王书杰. 我如何诊断和治疗获得性血友病A[J]. 中华血液学杂志, 2021, 42(3): 193-198. WANG Shujie. How I diagnose and treat acquired hemophilia A [J]. Chinese Journal of Hematology, 2021, 42(3): 193-198.
[6] Vetri D, Lumera G, Tarascio S, et al. A case of acquired factor V deficiency in patient with bleeding [J]. TH Open, 2020, 4(2): e77-e79.
[7] Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, et al. Younger age at presentation of acquired haemophilia a in Asian countries: a single-centre study and systematic review [J]. Haemophilia, 2014, 20(3): 205-210.
[8] 杨仁池. 获得性血友病A诊断与治疗中国专家共识解读[J]. 临床血液学杂志, 2014, 27(4): 547-549. YANG Renchi. Comments on Chinese experts consensus on the diagnosis and treatment of acquired hemophilia A [J]. Journal of Clinical Hematology, 2014, 27(4): 547-549.
[9] Knöbl P, Lechner K. Acquired factor V inhibitors [J]. Baillieres Clin Haematol, 1998, 11(2): 305-318.
[10] Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review[J]. J Thromb Thrombolysis, 2011, 31(4): 449-457.
[11] Coppola A, Favaloro EJ, Tufano A, et al. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A [J]. Semin Thromb Hemost, 2012, 38(5): 433-446.
[12] Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A [J]. Haematologica, 2020, 105(7): 1791-1801.
[13] Koyama T, Saito T, Kusano T, et al. Factor V inhibitor associated with Sjögrens syndrome [J]. Br J Haematol, 1995, 89(4): 893-896.
[14] Kapur A, Kelsey PR, Isaacs PE. Factor V inhibitor in thrombosis [J]. Am J Hematol, 1993, 42(4): 384-388.
[15] Kamphuisen PW, Haan J, Rosekrans PC, et al. Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features [J]. Am J Hematol, 1998, 57(2): 176-178.
[16] Kalafatis M, Simioni P, Tormene D, et al. Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations [J]. Blood, 2002, 99(11): 3985-3992.
[17] Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry(EACH2)[J]. J Thromb Haemost, 2012, 10(4): 622-631.
[18] Holstein K, Liu X, Smith A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A results from the GTH AH 01 2010 study [J]. Blood, 2020,136(3): 279-287.
[19] Baudo F, Collins P, Huth-Kühne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia(EACH2)Registry [J]. Blood, 2012, 120(1): 39-46.
[20] Menegatti M, Biguzzi E, Peyvandi F. Management of rare acquired bleeding disorders [J]. Hematology Am Soc Hematol Educ Program, 2019, 2019(1): 80-87.
[21] Sun B, Xue F, Feng Y, et al. Outcome of CARE: a 6-year national registry of acquired hemophilia A in China [J]. Br J Haematol, 2019, 187(5): 653-665.
[22] Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII(recombinant), porcine sequence, in subjects with acquired haemophilia A [J]. Haemophilia, 2015, 21(2): 162-170.
[23] Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A[J]. Blood, 2021,137(3):410-419.
[24] Gavva C, Yates SG, Rambally S, et al. Transfusion management of factor V deficiency: three case reports and review of the literature [J]. Transfusion, 2016, 56(7): 1745-1749.
[25] Tracy PB, Eide LL, Bowie EJ, et al. Radioimmunoassay of factor V in human plasma and platelets [J]. Blood, 1982, 60(1): 59-63.
[26] Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V [J]. J Clin Invest, 1986, 77(2): 405-415.
[27] Liu W, Liu J, Xue F, et al. Anti-CD38 antibody for refractory acquired hemophilia A [J]. J Thromb Haemost, 2023. doi: 10.1016/j.jtha.2023.03.010.
[28] Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry(EACH2)[J]. Blood, 2012, 120(1): 47-55.
[29] Schep SJ, van Dijk WEM, Beckers EAM, et al. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study [J]. Am J Hematol, 2021, 96(1): 51-59.
[1] XU Ge, LI Qing, ZHANG Cancan, TIAN Yongjie. Expressions and clinical significance of PARP-1 and HIF-1α in adenomyosis tissues and primary cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 55-61.
[2] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[3] MIN Aoxue, ZHU Tianrui, ZHANG Feng, WANG Ranran, LI Xiaohong. Effects of A151 on the polarization of BV-2 cells induced by glucose and oxygen deprivation and lipopolysaccharide [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 1-9.
[4] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7-14.
[5] JIANG Lijuan, LIU Fuqiang, JIANG Ziyun, LI Wenjuan, LIN Peng, WANG Chuan, HOU Xinguo, CHEN Li. Dapagliflozin improves lipid metabolism and visceral adipose tissues in overweight and obese patients with type 2 diabetes [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 87-93.
[6] SHI Shuyuan, GUAN Zhiyu, SUN Daqiang. Recombinant human vascular endostatin enhances antitumour activity of EGFR-TKIs for lung cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 6-10.
[7] DING Changkuan, Jason Chen. Effects of proteasome inhibitor bortezomib combined with cisplatin on proliferation of human cervical cancer cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 70-75.
[8] GAO Jianbu, YANG Shouzhong, LI Yudong, QIAO Chong, ZHANG Songyu. Trend survey of inpatient use of drugs for acute myocardial infarction during 10 years in a hospital of Nanyang City [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 66-69.
[9] LIN Jiaxiang, GUO Zijia, SU Peng, WANG Xiao, GUO Yaxin, WU Xiaojuan, XIANG Lei, ZHOU Zhiqiang, WANG Yan, CUI Xiujie, PAN Aifeng, GUO Chenghao. The role of CIP2A in the transformation of breast ductal epithelium and prognosis of invasive breast cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 100-106.
[10] LI Hongzhi, SHEN Yongchao, LIU Jieting, ZHAO Xiaojin, CHU Yanhui, YUAN Xiaohuan. An 11β-HSD1 inhibitor improves insulin sensitivity in db/db mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 59-64.
[11] WANG Wei, CAO Yushan, SUN Daquan, HUANG Xiaoqiong, XU Guoqiang. Role of human TIMP-2 protein in the migration and invasion of hepatocellular carcinoma cell [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 11-17.
[12] ZHANG Bohua, WANG Yue, YANG Yongxin, SONG Jingjie, ZHANG Shengwei, HU Shuang, SHENG Jie, TAN Meng, FENG Ye. Inhibitory control ability of ERP research on internet addiction disabilities based on personality types of traditional Chinese medicine [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 76-81.
[13] ZHAO Lu, SUN Junbo, WEI Guimei. MRP8 regulates expression of IL-1β in gout cell model by NF-κB signaling pathway [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 44-47.
[14] SUN Hongxiang, CHEN Ping, JIAO Zezhao, YUE Su, JIN Tianyun, XIANG Lan. Essential oils of Alpiniae Oxyphyllae Fructus before and after salt-fried:GC-MS analysis and their anti-acetylcholinesterase activity [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 27-32.
[15] ZHANG Wei, ZHOU Yong, NIU Junjie, XU Ying, HOU Huaying, JIANG Yuhua. Radioprotective effects of valproic acid on normal brain tissues of rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(10): 11-15.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd